Physician

Khalil A. Katato, M.D.

According to 2025 Medicare claims, Khalil Katato, M.D. (NPI: 1477518629) practices hematology/oncology in the Flint, MI market, with the plurality of this provider's patient population coming from Genesee, MI. This provider's primary affiliated billing organization is GENESEE HEMATOLOGY-ONCOLOGY, P.C. (NPI: 1902977101; TIN: 382278871) and primary practice location at 48503-2044. Katato is affiliated with the POM ACO (ACO ID: A1297) and Genesys PHO, L.L.C. (ACO ID: A2597), participating under the MSSP model.

Katato's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 478 traditional Medicare patients, billed 109,285 HCPCS/CPT codes, and received $1,613,563 in Medicare payments. The top billing code was 99222 (Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes). Part D data shows 1,952 prescription claims across 315 beneficiaries totaling $4,623,330 in drug costs, led by Xtandi (Enzalutamide). DME data shows 26 claims. Open Payments data shows 79 records totaling $2,106. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $2,169,463 to $1,613,563. In contrast, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,161,297 to $4,623,330. For DME billing, this smaller-volume category started with an early spike, then settled into a lower baseline, moving from $4,515 to $1,537.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	535	148,747	$2,169,463
2016	593	120,980	$1,697,083
2017	627	153,176	$2,129,198
2018	606	163,185	$2,265,586
2019	583	126,649	$1,877,110
2020	506	85,556	$1,431,987
2021	512	108,389	$1,693,644
2022	501	118,256	$1,661,910
2023	464	66,275	$1,047,723
2024	478	109,285	$1,613,563

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	313	1,375	$1,161,297
2016	352	1,507	$1,425,373
2017	347	1,851	$1,849,294
2018	401	2,076	$2,734,480
2019	359	2,057	$3,191,079
2020	345	2,057	$3,789,100
2021	291	1,904	$3,942,879
2022	262	1,524	$3,208,012
2023	313	1,744	$3,920,450
2024	315	1,952	$4,623,330

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	55	$2,491
2016	N/R	11	$158
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	24	$873
2023	N/R	46	$1,762
2024	N/R	26	$950

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	84	87	$95
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	79	168	$88
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	170	287	$60
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	73	124	$45
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	305	812	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	47	1,410	$621,544
Qinlock	Ripretinib	12	360	$495,695
Idhifa	Enasidenib Mesylate	14	421	$439,753
Imbruvica	Ibrutinib	26	728	$419,276
Revlimid	Lenalidomide	16	448	$326,271

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	13	$776
E0431	Portable gaseous oxygen system, rental; includes portable container, regulator, flowmeter, humidifier, cannula or mask, and tubing	Y	N/R	13	$174

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	79	$2,106	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Khalil A. Katato, M.D.?

Tedicare shows public-source Medicare data for Khalil A. Katato, M.D. (NPI 1477518629), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Khalil A. Katato, M.D. have ACO affiliation data?

Khalil A. Katato, M.D. is shown with ACO affiliation data for POM ACO (MSSP, ACO ID A1297) and Genesys PHO, L.L.C. (MSSP, ACO ID A2597).

What billing organization is linked to Khalil A. Katato, M.D.?

Khalil A. Katato, M.D. is linked to GENESEE HEMATOLOGY-ONCOLOGY, P.C. (billing NPI 1902977101) in the available physician profile data.

Does Khalil A. Katato, M.D. have Open Payments data?

Khalil A. Katato, M.D. has 79 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.